Zhong Nanshan team novel coronavirus pneumonia has a good inhibitory effect on the new crown pneumonia.

Recently, China's novel coronavirus pneumonia was treated by Lianhua Qingwen granule, which is affiliated to Pu Ren Hospital of Wuhan University of Science and Technology, Wuhan Ninth Hospital and Huarun general hospital They were published in the World Journal of Chinese medicine, Chinese medicine magazine and Chinese Journal of experimental medicine 54 cases of novel coronavirus pneumonia were treated by Lianhua Qingwen granule and the conventional treatment of Pu Ren Hospital Affiliated to Wuhan University of Science and Technology The research showed that after 3 days of treatment, the disappearance rate of fever, fatigue and cough were 47.5%, 35.1% and 20% respectively After treatment for 5 days, the rate of fever, fatigue and cough disappeared 62.5%, 59.5%, 50% respectively The disappearance rates of symptoms were 80.0%, 75.7% and 76.7% respectively; the disappearance rates of chest distress, dyspnea and moist rales were 84.6%, 100% and 89.5% respectively; the effective rate was 81.6%, and the clinical application was safe The novel coronavirus pneumonia was significantly improved by the Lianhua Qingwen granule The fever, cough and fatigue were all observed in the patients with common fever 42 patients with novel coronavirus pneumonia were diagnosed in the Ninth Hospital of Wuhan and Huarun General Hospital of Wuhan Iron and steel group The results showed that: Lianhua Qingwen treatment group can significantly alleviate the clinical symptoms of fever, cough, expectoration, shortness of breath, especially in improving the fever symptoms, showing a unique advantage The disappearance time of fever was 1.5 days shorter than that of the control group on average, and it can also improve fatigue, muscle pain and other symptoms Compared with the control group, the disappearance rate of fever symptoms in the treatment group was 85.7% (57.1% in the control group), the disappearance rate of cough symptoms in the treatment group was 46.7% (5.6% in the control group), the difference between the two groups was statistically significant; compared with the control group, the disappearance rate of expectoration in the treatment group was 64.3% (9.1% in the control group), and the disappearance rate of shortness of breath symptoms was 77.8% (0 in the control group), the difference was statistically significant 101 cases of suspected novel coronavirus pneumonia were treated in the Huarun General Hospital of WISCO, Wuhan University of Science and Technology 63 cases were treated with Lianhua Qingwen treatment group and 38 cases in the control group The results showed that Lianhua Qingwen could significantly improve the symptoms of fever, cough and fatigue, and shorten the fever time for 1 days Compared with the control group, the disappearance rates of fever, cough and asthenia in the treatment group were 86.7%, 55.6% and 82.5%, respectively, which were significantly better than those in the control group The disappearance rate of dyspnea and moist rales in the treatment group was significantly higher than that in the control group In February 18th, novel coronavirus and Professor Zhong Nanshan, a professor of the national respiratory disease laboratory at Guangzhou Medical University, pointed out that the research of cell models for Lianhua Qingxin against new coronavirus and its anti-inflammatory activity showed that Lianhua Qingwen caused a fine infection of common coronavirus (HCoV-229E) and new coronavirus (COVID-19), and the infection of the virus was also caused by the infection of common scars (COVID-19) Cytopathy has a good inhibitory effect In addition, Lianhuaqingwen can inhibit the expression of TNF - α, IL-6, CCL2 / MCP-1 and cxcl-10 / IP-10 inflammatory factors induced by hcov-229e and covid-19 infected cells The novel coronavirus displayed a novel coronavirus at the cell level, showing the anti viral and anti-inflammatory effects, and it brought hope for the treatment of new coronavirus infection Novel coronavirus pneumonia was also used in the clinical practice of Zhong Nanshan, academician of the Chinese Academy of Sciences Lianhua Qingwen capsule / granule played a great role in the prevention and control of the epidemic At the beginning of the epidemic, lingyao pharmaceutical industry immediately donated 10 million yuan worth of Lianhua Qingwen capsule to the Red Cross Society of China to send it to the epidemic area, so as to let the patients use the medicine as soon as possible Subsequently, the drug supply in the epidemic area of Hubei Province was guaranteed to reach 9 million boxes, and it was roughly estimated that 450000 people in Hubei Province used Lianhuaqingwen At present, all the shelter hospitals in Wuhan also use Lianhuaqingwen as the basic medicine A novel coronavirus pneumonia diagnosis and treatment plan (released in fifth and revised version) by the national health and Health Committee, as well as the diagnosis and treatment plan of 19 provinces and municipalities in Shandong, Hebei, Zhejiang and Hubei, is recommended as a clinical recommendation.